How does Bravecto work on a dog? - briefly
Bravecto works by releasing fluralaner into the dog's bloodstream over an extended period of time. This active ingredient targets and kills fleas and ticks by disrupting their nervous systems, providing continuous protection against these parasites for up to 12 weeks.
How does Bravecto work on a dog? - in detail
Bravecto is a novel, highly effective ectoparasiticide that has revolutionized the way we manage flea and tick infestations in dogs. Its active ingredient, fluralaner, belongs to the class of isoxazolines, which are known for their potent insecticidal and acaricidal properties. The mechanism of action of Bravecto involves several key steps that collectively ensure its efficacy against a wide range of ectoparasites.
Upon administration, fluralaner is rapidly absorbed into the dog's bloodstream, where it begins to exert its effects on fleas and ticks. The primary mode of action involves inhibiting the function of GABA (gamma-aminobutyric acid) receptors and glutamate-gated chloride channels in the parasites' nervous system. These receptors are crucial for normal neuronal transmission, and their disruption leads to an uncontrolled influx of chloride ions into the nerve cells. This results in a state of continuous stimulation, causing paralysis and eventual death of the ectoparasites.
One of the remarkable features of Bravecto is its long-lasting efficacy. Once ingested, fluralaner persists in the dog's system for an extended period, typically up to 12 weeks depending on the formulation used (Bravecto Spot-On or Bravecto Chewable). This prolonged activity is due to the slow release of the active ingredient from adipose tissue, where it accumulates after initial absorption. The sustained release ensures continuous protection against fleas and ticks, minimizing the risk of reinfestation.
In addition to its direct effects on ectoparasites, Bravecto also exhibits larvicidal activity. When adult fleas feed on a dog treated with Bravecto, they ingest fluralaner, which is then transferred to their eggs. The active ingredient disrupts the development of flea larvae, preventing them from hatching and further perpetuating the infestation cycle. This dual action—killing adult parasites while also preventing the reproduction of new generations—contributes significantly to the overall effectiveness of Bravecto in controlling flea populations.
Bravecto's safety profile is another notable aspect of its mechanism of action. The drug has been designed to target specific receptors found predominantly in ectoparasites, minimizing off-target effects on mammalian systems. This selectivity reduces the likelihood of adverse reactions in treated dogs, making Bravecto a reliable choice for pet owners seeking effective and safe parasite control.
In summary, Bravecto's mechanism of action involves the inhibition of GABA receptors and glutamate-gated chloride channels in ectoparasites, leading to paralysis and death. Its long-lasting efficacy is due to the slow release of fluralaner from adipose tissue, providing continuous protection for up to 12 weeks. Additionally, Bravecto exhibits larvicidal activity, preventing the development of flea larvae and breaking the infestation cycle. The drug's safety profile is further enhanced by its selective targeting of parasite-specific receptors, ensuring minimal adverse effects in treated dogs.